Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C9 Polymorphism and Unstable Anticoagulation with Warfarin in Patients Within the First 3 Months Following Heart Valve Replacement.

Advances in clinical and experimental medicine : official organ Wroclaw Medical University - 1 Jan 2000

Wypasek Ewa, Cieśla Marek, Suder Bogdan, Janik Łukasz, Sadowski Jerzy, Undas Anetta

Abstract excerpt

BACKGROUND: Warfarin dose requirements are partly determined by common single nucleotide polymorphisms in VKORC1 and CYP2C9 genes. OBJECTIVES: The aim of this study was to investigate how the presence of allelic variants in CYP2C9 affects the stability of anticoagulation in patients within the first 3 months following elective heart valve replacement. MATERIAL AND METHODS: In a case-control study we compared 18...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Blood Coagulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Drug Monitoring

Share to Heart Valve Prosthesis Implantation

Share to International Normalized Ratio

Share to Poland

Share to Warfarin

Source

Identifiers

PMID: 26469104
DOI: 10.17219/acem/32577

Genes

TTR
VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C9 Polymorphism and Unstable Anticoagulation with Warfarin in Patients Within the First 3 Months Following Heart Valve Replacement.PMID 26469104Read ↗

The role of CYP2C9 gene polymorphisms on anticoagulant therapy after heart valve replacement.Semantic proximity Read ↗

Factors influencing quality of anticoagulation control and warfarin dosage in patients after aortic valve replacement within the 3 months of follow up.Semantic proximity Read ↗

Integrated analysis of clinical and genetic factors on the interindividual variation of warfarin anticoagulation efficacy in clinical practice.Semantic proximity Read ↗

Association between gene polymorphisms and initial warfarin therapy in patients after heart valve surgery.Semantic proximity Read ↗

Genetic influence on bleeding and over-anticoagulation risk in patients undergoing warfarin treatment after heart valve replacements.Semantic proximity Read ↗

The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment.Semantic proximity Read ↗

Genotype-Guided Warfarin Dosing in Patients With Mechanical Valves: A Randomized Controlled Trial.Semantic proximity Read ↗

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.Semantic proximity Read ↗

Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.Semantic proximity Read ↗

Influence of CYP2C9 polymorphism on the fall in International Normalized Ratio in patients interrupting warfarin therapy before elective surgery.Semantic proximity Read ↗

Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.Semantic proximity Read ↗

CYP2C9, VKORC1, CYP4F2, ABCB1 and F5 variants: influence on quality of long-term anticoagulation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.